Cost-Utility Analysis of Genetic Screening for MUTYH Mutations
Author Information
Author(s): Maartje Nielsen, Frederik J. Hes, Hans F.A. Vasen, Wilbert B. van den Hout
Primary Institution: Leiden University Medical Center
Hypothesis
What are the economic implications of genetic screening in families of patients with MUTYH mutations?
Conclusion
Genetic screening in families of MAP patients is cost-effective and should be offered to counselees.
Supporting Evidence
- The cost per quality-adjusted life year (QALY) for genetic screening was estimated at €25,000.
- The cost-utility ratio increased slightly to €25,500 per QALY with the presence of population screening.
- For a heterozygote index patient, the cost per QALY was €51,500.
Takeaway
This study looks at how much it costs to test families for a gene that can cause cancer, and it finds that the costs are reasonable.
Methodology
A Markov model was constructed to perform a societal cost-utility analysis using data from Dutch MAP patients.
Potential Biases
Potential biases may arise from the reliance on existing literature and assumptions made in the model.
Limitations
The model's accuracy is limited by the availability of reliable data and does not account for all potential health risks associated with MUTYH mutations.
Participant Demographics
Participants were Dutch MAP patients, with a focus on families affected by MUTYH mutations.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website